Related Experiment Videos
Mechanism based chemotherapy for prostate cancer
1Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111.
Cancer Surveys
|January 1, 1991
Summary
Estramustine, a novel prostatic cancer therapy, targets microtubule-associated proteins, inhibiting cell division. Combination therapy with vinblastine shows promise for advanced disease.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Prostatic cancer treatment often requires novel therapeutic strategies.
- Estramustine represents a mechanistically distinct approach to cancer therapy.
- The drug's composition involves oestradiol linked to nor-nitrogen mustard.
Purpose of the Study:
- To investigate the mechanism of action of estramustine in prostatic cancer.
- To explore the drug's interaction with microtubule-associated proteins (MAPs).
- To evaluate the efficacy of estramustine, alone and in combination, for advanced hormone-refractory disease.
Main Methods:
- In vivo and in vitro studies were conducted.
- Drug binding to microtubule-associated proteins was assessed.
- Mitotic processes were analyzed at the micromolar estramustine concentration.
- Clinical trials involving estramustine and vinblastine were performed.
Main Results:
- Estramustine's cytotoxic effects are independent of its constituent molecules.
- The drug binds to MAPs, inhibiting microtubule-regulated processes.
- Micromolar estramustine concentrations inhibit specific mitotic events, indicating differential MAP sensitivity.
- Combination therapy with vinblastine demonstrated clinical potential.
Conclusions:
- Estramustine offers a novel mechanism for prostatic cancer treatment by targeting MAPs.
- Differential sensitivity of microtubules/MAPs to estramustine warrants further investigation.
- Combining estramustine with vinblastine may be a clinically significant strategy for advanced disease.